Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12415429 | 0.91 | KMT2A (0.57) | KMT2AMEN1TDP1HSP90AA1POLB | |
| SCHEMBL1923326 | 0.85 | KMT2A (0.55) | KMT2AMEN1TDP1HSP90AA1POLB | |
| SCHEMBL3695711 | 0.84 | KMT2A (0.54) | KMT2AMEN1TDP1HSP90AA1POLB | |
| SCHEMBL12589784 | 0.84 | KMT2A (0.59) | KMT2AMEN1TDP1HSP90AA1POLB | |
| SCHEMBL10364639 | 0.81 | MEN1 (0.57) | KMT2AMEN1TDP1HSP90AA1POLB | |
| SCHEMBL12418678 | 0.80 | MEN1 (0.56) | KMT2AMEN1TDP1HSP90AA1POLB | |
| SCHEMBL9272801 | 0.80 | MEN1 (0.47) | KMT2AMEN1TDP1HSP90AA1POLB | |
| SCHEMBL10769481 | 0.79 | KMT2A (0.52) | KMT2AMEN1TDP1HSP90AA1POLB | |
| SCHEMBL1969687 | 0.79 | KMT2A (0.52) | KMT2AMEN1TDP1HSP90AA1POLB | |
| SCHEMBL12394779 | 0.79 | MEN1 (0.76) | KMT2AMEN1TDP1HSP90AA1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172096-A1 | Triazole Compounds, The Use Thereof and Preparations Containing These Compounds | BASF SE (DE) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172096-A1 | Triazole Compounds, The Use Thereof and Preparations Containing These Compounds | CYP11B2, CYP3A43, CYP3A5 | KMT2A 3160/4885MEN1 625/4885TDP1 1251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.